AstraZeneca said it would
sell the European rights to acid-reflux medicine Nexium to
Grunenthal for an upfront $700 million and future sales-related
payments of up to $90 million as it is not in the company’s
targeted therapy areas.

Read More At Article Source | Article Attribution